Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) EBIT Margin (2020 - 2025)

Treace Medical Concepts' EBIT Margin history spans 6 years, with the latest figure at 9.47% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 918.0% year-over-year to 9.47%; the TTM value through Dec 2025 reached 25.46%, up 114.0%, while the annual FY2025 figure was 25.46%, 114.0% up from the prior year.
  • EBIT Margin reached 9.47% in Q4 2025 per TMCI's latest filing, up from 31.22% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.3% in Q4 2024 to a low of 48.1% in Q2 2024.
  • Average EBIT Margin over 5 years is 26.08%, with a median of 30.38% recorded in 2023.
  • Peak YoY movement for EBIT Margin: crashed -3182bps in 2021, then skyrocketed 1228bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 16.74% in 2021, then skyrocketed by 58bps to 7.03% in 2022, then crashed by -55bps to 10.9% in 2023, then surged by 97bps to 0.3% in 2024, then crashed by -3090bps to 9.47% in 2025.
  • Per Business Quant, the three most recent readings for TMCI's EBIT Margin are 9.47% (Q4 2025), 31.22% (Q3 2025), and 35.82% (Q2 2025).